Chikungunya virus (CHIKV) has expanded its geographical reach in recent decades and is an emerging global health threat. CHIKV can cause significant morbidity and lead to chronic, debilitating arthritis/arthralgia in up to 40% of infected individuals. Prevention, early identification, and clinical m...anagement are key for improving outcomes. The aim of this review is to evaluate the quality, availability, inclusivity, and scope of evidence-based clinical management guidelines (CMG) for CHIKV globally.
more
La Enfermedad por el Virus de la Chikungunya – EVCH fue descrita por primera vez durante un brote ocurrido en 1952 al sur de Tanzania, su nombre es de origen makonde, grupo étnico que vive en esa región, que significa “aquel que se encorva” o “retorcido”, que describe la apariencia inc...linada de las personas que sufren la enfermedad, por las artralgias intensas que la caracterizan
more
Joint Action for Results
UNAIDS Outcome Framework: Business Case 2009–2011
Lancet. 2018 Dec 19. pii: S0140-6736(18)31647-7. doi: 10.1016/S0140-6736(18)31647-7. [Epub ahead of print]
Prompted by the 20th anniversary of the 1993 World
Development Report, a Lancet Commission revisited the
case for investment in health and developed a new
investment frame work to achieve dramatic health gains by 2035. Our report has four key messages, each accompanied by opportunities for action... by national governments of low-income and middle-income countries and by the international community.
more
Informe sobre poplaciones clave.
With the growing prevalence of type 2 diabetes, particularly in emerging countries, its management in the context of available resources should be considered. International guidelines, while comprehensive and scientifically valid, may not be appropriate for regions such as Asia, Latin America or Afr...ica, where epidemiology, patient phenotypes, cultural conditions and socioeconomic status are different from America and Europe. Although glycaemic control and reduction of micro- and macrovascular outcomes remain essential aspects of treatment, access and cost are major limiting factors; therefore, a pragmatic approach is required in restricted-resource settings. Newer agents, such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in particular, are relatively expensive, with limited availability despite potentially being valuable for patients with insulin resistance and cardiovascular complications. This review makes a case for the role of more accessible second-line treatments with long-established efficacy and affordability, such as sulfonylureas, in the management of type 2 diabetes, particularly in developing or restricted-resource countries.
more
Guidelines for Treatment and Management of Heart Failure in Indonesia
Воспитание детей при COVID-19
Советы родителям по воспитанию и мероприятия для всех возрастов
Parenting tips
Воспитание детей при COVID-19
Советы родителям по воспитанию и мероприятия для всех возрастов
Parenting tips
Impact Evalution Report 61